Phase II

Related by string. Phases II * phase . phases . Phases . PHASE . PHASES : Phase III clinical trials . Phase III trials . Phase III clinical . pivotal Phase III . Phase III / ii . IIS . IID . Ii : World War II . Queen Elizabeth II . Chart II . Hangover Part II * Initiates Phase II . SBIR Phase II . multicenter Phase II . Randomized Phase II . ACC5 Phase II . Initiate Phase II . Pivotal Phase II *

Related by context. All words. (Click for frequent words.) 88 Phase III 84 Phase 76 Phase IIb 75 Phase 2a 75 Phase 1b 74 Phase Ib 74 Phase III clinical 73 phase IIa 73 Phase 1a 73 phase IIa clinical 73 pivotal Phase III 72 Phase IIa 72 phase IIb 72 Phase Ib clinical 72 Phase 2b 71 Phase 2b trial 71 Phase 2a clinical 71 Phase IIa clinical 71 phase 2a 70 Phase IIb trial 70 Phase 2b study 69 phase Ib 69 Phase IIb clinical 69 Phase Ib II 69 Phase IIB 69 Phase 2b clinical 69 Phase 1b clinical 67 Phase IIa trial 66 Phase Ia 66 Phase III pivotal 66 Phase 2a trial 66 Phase Ib study 66 Phase #b/#a 66 phase IIb clinical 65 Phase IIIb clinical 65 pivotal Phase 65 dose escalation trial 65 Phase IV 65 Phase III clinical trials 65 GALNS 65 placebo controlled Phase 65 confirmatory Phase 3 65 dose escalation Phase 64 multicenter Phase II 64 IIa trial 64 Phase IIa trials 64 multicenter Phase 64 confirmatory Phase III 64 Phase 2b clinical trials 63 Phase IIIb 63 Phase 1a clinical 63 BRIM2 63 dose escalation clinical 63 randomized Phase 63 phase Ib clinical 63 Phase IIb trials 63 Phases II 63 Phase III trials 63 multicenter randomized Phase 63 initiate Phase 62 Phase 1b trial 62 IIb clinical trial 62 dose escalation study 62 randomized Phase IIb 62 Phase III confirmatory 62 APEX PD 62 multiple ascending dose 62 phase 62 MEND CABG 62 Phase IIb clinical trials 62 initiate Phase IIb 62 GLP toxicology studies 61 registrational 61 clinical trial 61 Cloretazine R VNP#M 61 BRIM3 61 phase IIb trial 61 Phase 2a clinical trials 61 INCB# [001] 61 Phase #b/#a clinical 60 TMC# [002] 60 IND enabling 60 alvespimycin 60 Initiated Phase 60 Zerenex 60 randomized controlled Phase 60 randomized Phase 2b 60 Phase III psoriasis 60 Initiate Phase 60 Urocidin 60 initiate Phase Ib 60 Phase IIb III 60 Phase III Pivotal 60 Phase IIA 60 Phase Ib clinical trials 60 IIa trials 60 Archexin 59 phase IIb study 59 placebo controlled Phase III 59 ongoing Phase 1b 59 PSMA ADC 59 pivotal bioequivalence 59 multicenter phase 59 ADVANCE PD 59 dose escalation 59 placebo controlled clinical 59 multicenter randomized placebo controlled 59 initiate Phase 2b 59 placebo controlled 59 Phase Ib IIa 59 SUCCEED trial 59 registrational trial 59 aclidinium bromide 59 preclinical 59 Phase #/#a 59 Elagolix 59 FORTIS M trial 59 Pivotal Phase 59 Pivotal Phase III 58 JAK inhibitor 58 HuMax EGFr 58 confirmatory Phase 58 Exherin TM 58 phase IIb III 58 blinded randomized placebo controlled 58 randomized controlled multicenter 58 mertansine 58 multicenter dose escalation 58 R#/MEM # 58 BCX# 58 NP2 Enkephalin 58 Phase 2b kidney transplant 58 Phase 1b clinical trials 58 dependent kinase inhibitor 58 evaluating mipomersen 58 European Sepsis Trial 58 Phase lll 58 IIa clinical 58 Investigational Device Exemption IDE 58 huN# DM1 58 opioid induced bowel dysfunction 58 ENDEAVOR IV 58 Phase1 58 IIa clinical trial 58 IMPACT IMmunotherapy 58 AZX# Phase 58 PFO migraine 58 Phase III randomized controlled 58 rALLy clinical trial 58 Cloretazine ® 58 Phase III HEAT 58 PANVAC VF 58 Phase IIb kidney transplant 58 cannabinor 58 single ascending dose 57 Fx #A 57 Phase III placebo controlled 57 TBC# 57 Pre RELAX AHF 57 Phase IIb Trial 57 VICTOR E1 57 LUVENIQ 57 BLA filing 57 midstage trials 57 randomized Phase III 57 Phase 1b dose escalation 57 IMPACT DCM 57 Ozarelix 57 Phase III registrational 57 TG MV 57 IND submission 57 KRN# 57 lintuzumab 57 pharmacodynamic PD 57 selectin antagonist 57 Biopharmaceuticals AG 57 Luveniq 57 PRX # 57 TASKi2 57 Phase IIa proof 57 Aplidin 57 OPT CHF 57 Pivotal Trial 57 ASA# 57 IMC #B 57 torezolid phosphate 57 REOLYSIN ® 57 Fodosine 57 NO# [002] 57 PDE4 inhibitor 57 tramiprosate Alzhemed TM 57 Phase IIa clinical trials 57 LUMINATE 57 deforolimus 57 EOquin 57 IMGN# 57 oral ridaforolimus 57 initiate Phase 1b 57 AP# [003] 57 initiated Phase Ib 57 pharmacokinetic PK study 57 AMPAKINE CX# 57 multicenter Phase III 56 Flutiform ™ 56 double blinded placebo 56 lorcaserin Phase 56 CB2 selective receptor agonist 56 huC# DM4 56 PI3K/Akt pathway inhibitor 56 Phase III Clinical Trial 56 Amrubicin 56 Phase #/#a clinical 56 treatment naive genotype 56 generation PNP inhibitor 56 Phase 2b randomized 56 LUX Lung 56 Aryplase 56 Zenvia Phase III 56 XL# [003] 56 IIa clinical trials 56 ATL# [001] 56 forodesine 56 RSD# oral 56 lorvotuzumab mertansine 56 Pivotal Trials 56 AeroLEF TM 56 initiate Phase IIa 56 Scopus Affiliation Identifier 56 ALN VSP Phase 56 Phase #b/#a trial 56 trastuzumab emtansine T DM1 56 LibiGel Phase III 56 MOZOBIL 56 MEND CABG II 56 Restanza 56 oral deforolimus 56 JunJing II 56 glufosfamide 56 Oglemilast 56 trodusquemine 56 ozarelix 56 ascending dose 56 TMC# C# 56 Fibrillex TM 56 double blinded randomized 56 immunosuppressive compound 56 pharmacokinetic PK 56 Zemplar Capsules 56 Dextofisopam 56 AQ4N 56 TKB# 56 oral prodrug 56 Androxal TM 56 dose cohort 56 cathepsin K inhibitor 56 omacetaxine mepesuccinate 56 L BLP# 56 multicentre randomized 56 clinical trials 56 Phase III multicenter 56 EOquin TM 56 bapineuzumab AAB 56 phase IIIb 56 PrevOnco ™ 56 multicenter clinical 56 drug pipeline TAFA# 56 randomized multicentre 56 PREOS R 56 Albuferon Phase 56 metastatic hormone refractory 56 OvaRex R 56 multicenter randomized double 56 ILLUMINATE 56 oral treprostinil 56 Multiple Ascending Dose 56 trastuzumab DM1 T DM1 56 trastuzumab DM1 56 dosing cohort 56 Successfully Completes Phase 56 laquinimod 56 relapsed refractory multiple myeloma 56 RESTORE CLI trial 56 LBH# 56 elotuzumab 56 PF # [002] 56 bardoxolone 56 ENRICH trial 56 Phase 2b monotherapy 55 seliciclib CYC# 55 BLA submission 55 Testosterone MDTS ® 55 MIST II 55 CEQ# 55 IMC A# 55 mipomersen 55 OHR/AVR# 55 AKT inhibitor 55 Anturol TM 55 compound INCB# 55 clinical trials Multikine 55 reslizumab 55 riociguat 55 dose escalation phase 55 Bayer HealthCare Onyx Pharmaceuticals 55 Daclizumab 55 IMA# 55 treatment naïve genotype 55 Maximum Tolerated Dose 55 ZYBRESTAT 55 PEG PAL 55 Phase III Trial 55 GetGoal Phase III 55 OLpur TM H2H 55 SYMMETRY trial 55 OvaRex ® MAb 55 OncoGel 55 AIMM trial 55 Corlux 55 MAP# 55 FOLOTYN ® 55 randomized placebo controlled 55 Phase IIb Clinical Trial 55 preclinical toxicology 55 obatoclax 55 BLOOM DM 55 TASKi3 55 selective androgen receptor modulator 55 Tarceva TM 55 Dacogen injection 55 Phase III Psoriasis 55 Eniluracil 55 Panzem R NCD 55 AIR CF2 55 ELACYT 55 bavituximab monotherapy trial 55 FDA Investigational Device 55 Initiates Phase II 55 PXD# 55 Vicriviroc 55 II Clinical Trial 55 AVADO 55 initiate multicenter 55 denosumab oncology 55 VALOR trial 55 tanespimycin 55 Pimavanserin 55 Prostate AdenoCarcinoma Treatment 55 confirmatory clinical 55 Curaxin CBLC# 55 budesonide foam 55 farletuzumab 55 thorough QT 55 BrachySil TM 55 bicifadine 55 methylnaltrexone 55 REG2 55 Phase IIB clinical 55 IND Investigational New 55 Omnitarg 55 Diamyd ® 55 IDX# 55 transmucosal delivery system 55 ThermoDox R 55 Allovectin 7 55 axitinib 55 preclinical efficacy 55 REVIVE Diabetes 55 Phase 2b Clinical Trial 55 neratinib 55 Mipomersen 55 alvimopan 54 QLT# 54 YONDELIS 54 Aclidinium 54 AeroLEF 54 tolevamer 54 randomized multicenter 54 CR# vcMMAE 54 PD LID 54 Commences Phase 54 MGCD# [001] 54 Phenoptin 54 label multicenter 54 CAMMS# 54 SEPET TM 54 PRESEPT 54 confirmatory pivotal 54 hypoxia activated prodrug 54 investigational humanized monoclonal antibody 54 Phase Ib IIa clinical 54 prospective multicenter randomized 54 Genasense oblimersen sodium Injection 54 Proxinium TM 54 multicenter randomized controlled 54 Initiate Phase II 54 TACI Ig 54 novel histone deacetylase 54 investigational protease inhibitor 54 Zybrestat 54 Tyrima 54 fostamatinib 54 HspE7 54 Triolex 54 label dose escalation 54 midstage clinical 54 Proellex TM 54 enzastaurin 54 PEG SN# 54 peginesatide 54 dose cohorts 54 T DM1 54 VNP#M 54 Levacor 54 Darusentan 54 pharmacokinetics PK 54 Vitaxin 54 rindopepimut 54 Aurexis 54 masked placebo controlled 54 Efficacy Trial 54 albiglutide 54 Benlysta belimumab 54 Randomized Phase 54 histone deacetylase HDAC inhibitor 54 assessing T DM1 54 RSD# 54 Urocortin 2 54 docetaxel Taxotere R 54 StemEx 54 rALLy trial 54 TOLAMBA 54 Randomized Phase II 54 CCR5 mAb 54 CRMD# 54 phase III ACCLAIM 54 Huaiyin Power Plant 54 PHX# 54 Annamycin 54 cetrorelix 54 Plicera 54 OncoVEX GM CSF 54 Capesaris 54 ABSORB trial 54 labial herpes 54 evaluating RDEA# 54 ZYBRESTAT fosbretabulin 54 COSIRA trial 54 velafermin belinostat 54 MAXY alpha 54 velafermin 54 adecatumumab MT# 54 Gabapentin GR 54 MAA submission 54 AERAS-#/Crucell Ad# 54 Pivotal Study 54 XL# SAR# 54 fosbretabulin 54 Trofex 54 dosing cohorts 54 CDAD Clostridium difficile 54 volociximab 54 double blind placebo 54 Prodarsan 54 rNAPc2 54 Phase III Clinical Trials 54 registrational studies 54 Spiegelmer ® 54 receptor tyrosine kinase inhibitor 54 PEARL SC 54 Phase III VISTA 54 PROSTVAC TM 54 EXPLORE Xa 54 CHAMPION PCI 54 perifosine 54 Phase IIIB 54 PRT# 54 EndoTAG TM -1 54 Phase IIIb study 54 celgosivir 53 pharmacokinetic 53 candidates Dyloject TM 53 Thorough QT 53 LCP AtorFen 53 ENDEAVOR III 53 IMPACT DCM clinical 53 CCR5 antagonist 53 darusentan 53 cancer neuroendocrine tumor 53 baminercept 53 Augment Injectable 53 ITAX 53 neurogenic orthostatic hypotension 53 UPLYSO 53 Phase 2a proof 53 Zenvia ™ 53 opioid bowel dysfunction 53 oral opioid modulator 53 Enzastaurin 53 Viprinex TM 53 PIX# trial 53 MAGE A3 ASCI 53 randomized double 53 ganetespib 53 Aflibercept 53 PROVENGE ® 53 VEGF Trap 53 Ostarine 53 Tesetaxel 53 Pralatrexate 53 LEVADEX 53 Laquinimod 53 PDX pralatrexate 53 MVax 53 PLK1 SNALP 53 ToGA 53 Factor VIIa 53 PTH analogue 53 acyclovir Lauriad R 53 multicenter prospective 53 ALSYMPCA 53 lomitapide 53 HepeX B TM 53 Genz # 53 romidepsin 53 PRECISE Trial 53 CRLX# 53 LibiGel testosterone gel 53 dexanabinol 53 aclidinium 53 BIIB# 53 SparVax TM 53 PEG Interferon lambda 53 ANCHOR trial 53 palifosfamide Zymafos TM 53 NDA submission 53 Hedgehog antagonist 53 CLIRS 53 DSMB recommended 53 Apoptone 53 SNT MC# 53 Rifamycin SV MMX 53 ofatumumab 53 JunJing III 53 COU AA 53 SPIRIT FIRST 53 EGS# 53 generation purine nucleoside 53 eltrombopag 53 tezampanel 53 tremelimumab 53 blinatumomab 53 BEMA Buprenorphine 53 generation URAT1 inhibitor 53 sapacitabine 53 CIP TRAMADOL ER 53 Traficet EN 53 fidaxomicin Phase 3 53 ALD# 53 Diabetic Macular Edema 53 ThermoDox ® 53 TASQ 53 Phase III TRIST 53 PROTECT AF 53 lintuzumab SGN 53 Fast Tracked Phase 53 Dose escalation 53 label multicenter randomized 53 Pinglu Project 53 AEG# 53 sunitinib malate 53 sNDA submission 53 isavuconazole 53 PrevOnco 53 ularitide 53 HDAC Inhibitor 53 EchoCRT 53 BrachySil 53 CLIRS trial 53 imetelstat GRN#L 53 SAR# [004] 53 RhuDex 53 controlled multicenter 53 Dose Ranging Study 53 Alpharadin 53 ACCLAIM II 53 ocrelizumab 53 Asentar 53 ALKS 53 Quinamed 53 INCB# [002] 53 ACCEDE 53 ThGRF 53 Pivotal Phase II 53 HGS ETR1 53 advanced carcinoid 53 LymphoStat B Phase 53 dirucotide 53 vascular disrupting agent 53 CIP ISOTRETINOIN 53 AIR CF1 53 Phase III Trials 53 vidofludimus 53 BR.# 53 OncoVex 53 blinded randomized 53 rPA anthrax vaccine 53 Ofatumumab 53 EVEREST II 53 Second Pivotal Phase 53 ONCONASE R 53 Troxatyl 53 CCX# 53 pafuramidine 53 Feasibility Trial 53 Acetavance TM intravenous acetaminophen 53 IL# PE#QQR 53 prospective multicenter 53 Investigational 53 pertuzumab 53 incyclinide 53 Initiates Phase 53 Virulizin 53 SPIRIT III 53 anticancer compound 53 StemEx R 53 ixabepilone 53 confirmatory 53 orBec 53 ENDEAVOR IV clinical 53 Alzhemed TM 53 CONSERV 53 randomized #:#:# 53 Sapacitabine 53 Phase III randomized 53 talactoferrin 53 unblind 52 CUSTOM III 52 Matrix Phase 2b 52 Azedra 52 severe hypercholesterolemia 52 Dyloject TM 52 BST CarGel R 52 Ophena TM 52 dacetuzumab SGN 52 ARISE Phase III 52 NVA# 52 randomized controlled 52 Hyphanox 52 miconazole Lauriad R 52 metastatic castrate resistant 52 microplasmin 52 3 registrational trial 52 RDEA# 52 refractory CLL 52 vosaroxin 52 SCH # 52 investigational drug 52 voreloxin 52 DDP# 52 tezampanel NGX# 52 BESST 52 RELOVAIR ™ 52 Kahalalide F 52 inhaled AAT 52 Clinical Trial 52 bortezomib Velcade 52 Harry Palmin President 52 teduglutide 52 AMD# [003] 52 ABSORB clinical 52 biliary tract cancer 52 dacetuzumab 52 PF # [001] 52 HCV RESPOND 2 52 CLL8 52 PSN# [002] 52 TransMID 52 HuMax CD# 52 tesmilifene 52 oral methylnaltrexone 52 placebo controlled randomized 52 RhuDex ® 52 relapsing multiple sclerosis 52 GAMMAGARD 52 LEVADEX ™ 52 Hsp# Inhibitor 52 ruxolitinib 52 Ketotransdel 52 Phase 1b Clinical Trial 52 RenalGuard System TM 52 LymphoStat B TM 52 Cloretazine 52 dyskinesia PD LID 52 prospective randomized multicenter 52 PS# [001] 52 Allovectin 7 ® 52 AEGR 52 Oxypurinol 52 R#/MEM 52 Panzem R 52 lead Aganocide compound 52 HGS# 52 Syncria albiglutide 52 octreotide implant 52 trial evaluating Prochymal 52 randomized discontinuation 52 eniluracil 52 Lenocta 52 HCD# [002] 52 Pharmos pipeline 52 Phase 2b Trial 52 MKC# MT 52 apricitabine 52 elacytarabine 52 PROPEL trial 52 HuMax CD4 52 LB# [003] 52 QNEXA 52 antibody MAb 52 unblinding 52 preclinical pharmacokinetic 52 telaprevir dosing 52 Virulizin ® 52 Huntexil 52 Aplidin R 52 dextromethorphan quinidine 52 unique alkylating agent 52 label multicenter Phase 52 Phase III ThermoDox 52 Glybera R 52 Lenocta TM 52 registrational Phase 52 viral kinetic 52 Prosaptide 52 ILUVIEN ® 52 optimal dosing regimens 52 resource delineation 52 PRIMO CABG2 52 Nuvion 52 Onalta ™ 52 Phase 2a Clinical Trial 52 TLK# 52 non nucleoside HCV 52 Phase III metastatic melanoma 52 ANYARA 52 Completes Patient Enrollment 52 Lovaxin C 52 ZACTIMA 52 BLP# Liposome Vaccine 52 mGluR5 NAM 52 XIENCE V Stent System 52 ZYBRESTAT TM 52 PMA submission 52 NGX# 52 Trastuzumab DM1 52 eculizumab 52 Randomised 52 CVac 52 Trovax 52 vaginally administered lidocaine 52 multicentre 52 BEMA Granisetron 52 Imvamune R 52 Amigal 52 HCV SPRINT 52 exemption IDE 52 multicenter 52 Phase 2a Trial 52 TG# [001] 52 Fast Track designation 52 Denufosol 52 ANTEGREN 52 Pirfenidone 52 Telatinib 52 investigational compound 52 #:# randomization 52 Mtsare Khevi Field 52 Allovectin 7 R 52 Phase #/#a trial 52 Personalized Immunotherapy 52 Avastin adjuvant 52 stated Michelle Berrey 52 Medidur TM FA 52 TEMSO 52 Shigamabs ® 52 droxidopa 52 Serdaxin ® 52 MLN# 52 Bezielle 52 Initiates Clinical 52 galiximab 52 drug NP2 Enkephalin 52 leading oral taxane 52 advanced metastatic prostate 52 midstage studies 52 MIVI III 52 multicenter placebo controlled 52 ritonavir boosted danoprevir 52 Thorough QT Study 52 Saforis 52 CATIE AD 52 CUDC 52 Panzem ® 52 Investigational Device Exemption 52 brentuximab vedotin SGN 52 Sulonex 52 carfilzomib 52 novel oral anticoagulant 52 ENGAGE AF TIMI 52 Bioral Amphotericin B 52 MDV# 52 solanezumab 52 Lu AA# 52 blinded placebo controlled 52 clinical trials Archexin ® 52 Diamyd R 52 LEVADEX TM 51 diabetic neuropathic pain 51 GLPG# 51 Perifosine 51 catheter occlusion 51 BAY #-# 51 clinical trials Archexin 51 Exelixis XL# 51 Novolimus 51 SinuNase TM 51 Zenvia TM 51 New Drug IND 51 prospective randomized placebo 51 ospemifene 51 mitogen activated ERK kinase 51 Solorel 51 OLYMPIA registry 51 OMNARIS HFA 51 EVIZON TM 51 apricitabine ATC 51 UVIDEM 51 Phase 2a preventative 51 telomerase inhibitor drug 51 oxypurinol 51 Entereg TM 51 cutaneous T cell 51 Reolysin 51 Testosterone MDTS R 51 overactive bladder AA# 51 DEB# 51 tolerated dose MTD 51 preclinical studies 51 tiapamil 51 PA# [002] 51 nonclinical studies 51 Efficacy Results 51 denufosol 51 Sorafenib HCC Assessment 51 Guanilib 51 oral picoplatin 51 Biologics License Application BLA 51 Combination REOLYSIN R 51 REGEN trial 51 sequential dose escalation 51 OMP #M# 51 Ocrelizumab 51 NABTT 51 TRC# 51 randomized multicenter trial 51 Clinical Trial Evaluating 51 Relovair 51 canagliflozin 51 Civacir 51 tesetaxel 51 HGS ETR2 51 GRN#L 51 Glufosfamide 51 resminostat 51 gemcitabine Gemzar ® 51 Carfilzomib 51 GRNVAC1 51 nab paclitaxel 51 clinical pharmacology studies 51 AZD# 51 HIV integrase inhibitor 51 virus HCV protease inhibitor 51 CRx 51 visilizumab 51 Initiates Phase 2b 51 Rezular 51 ascending doses 51 oral taxane 51 cetrorelix pamoate 51 Advaxis Phase 51 CLL SLL 51 LibiGel ® 51 Pivotal Clinical Trial 51 Achieves Primary Endpoint 51 ZFP Therapeutic 51 urocortin 2 51 APPRAISE 51 ISIS # 51 Randomized Evaluation 51 TELCYTA 51 ACTIVE W 51 Atiprimod 51 Study Evaluating 51 VITAL Trial 51 AIR CF3 51 Xcellerated T Cells 51 NEO3 51 ASONEP 51 Alocrest 51 talabostat 51 Clonicel 51 acute peripheral arterial 51 nalbuphine ER 51 Biologics License Application 51 oral calcitonin 51 CALGB # [002] 51 crofelemer 51 OLpur TM MD 51 PRIMO CABG 51 multicentre randomized double 51 randomized multicenter Phase III 51 MERLIN TIMI 51 tamibarotene 51 metastatic CRPC 51 TORISEL TM 51 Degarelix 51 next generation URAT1 51 LAS# [002] 51 Omigard 51 polymerase inhibitor 51 relapsed multiple myeloma 51 oral sapacitabine 51 maximally tolerated dose 51 EINSTEIN DVT 51 controlled multicenter Phase 51 IIa Clinical Trial 51 balsalazide tablet 51 Amoxicillin PULSYS Phase III 51 evaluating nimotuzumab 51 ICA # 51 Alequel ™ 51 pharmacodynamic effects 51 Optiquel ™ 51 elagolix 51 RPL# 51 alemtuzumab Campath 51 including eniluracil ADH 51 non nucleoside inhibitor 51 INSPIRE Trial Phase III 51 APTIVUS 51 COSTAR II 51 GATTEX ™ 51 granted Ortec 51 maribavir 51 initiated Phase 1b 51 APF# Phase 51 EVIZON TM squalamine lactate 51 NOX E# 51 Rescula 51 Indibulin 51 Meets Primary Endpoint 51 ganaxolone 51 oral rivaroxaban 51 Lucanix R 51 ACAPODENE 51 midstage clinical trials 51 ORMD 51 apaziquone 51 unblinded 51 Oncoscience AG 51 multicenter randomized clinical 51 aflibercept 51 Sym# 51 dexpramipexole 51 PRECiSE 51 LymphoStat B belimumab 51 AzaSite Plus 51 Trial Evaluating 51 OXi# 51 MEK inhibitor RDEA# 51 FORTIS M 51 oglemilast 51 Zerenex ™ 51 proteasome inhibitor 51 Tofacitinib 51 GV# [001] 51 KNS # 51 Synavive 51 pomalidomide 51 Diamyd r vaccine 51 Onconase 51 NJ1 51 mg/m2 cohort 51 MGd 51 LEP ETU 51 Phase Ib Clinical Trial 51 STRIDE PD 51 paclitaxel poliglumex 51 ZALBIN dosed

Back to home page